交银国际研究 财务模型更新 | 医药 | 收盘价 | | 目标价 | | 潜在涨幅 | 2026 年 4 月 1 日 | | --- | --- | --- | --- | --- | --- | --- | | 港元 | | 22.64 | 港元 | 32.40↓ | +43.1% | | | 三生制药 (1530 HK) | | | | | | | 2025 年 BD 收入推动高增长， 商业化和 707 迎密集催化剂；维持买入 我们对于公司 2026 年展望如下：1）多个新产品和新适应症获批上市，有望 驱动产品销售收入重新回到较快增长轨道；2）707 海外快速推进注册临床， 并持续产生里程碑收入；3）股东回报有望强化。维持买入。 1 年股价表现 0% 50% 100% 150% 200% 250% 1530 HK 恒生指数 股份资料 | 52周高位 (港元) | 35.90 | | --- | --- | | 52周低位 (港元) | 10.12 | | 市值 (百万港元) | 56,546.80 | | 日均成交量 (百万) | 62.36 | | 年初至今变化 (%) | (6.37) | | 200 ...

Investment Rating - The report maintains a "Buy" rating for the company, Sanofi Pharmaceutical (1530 HK), with a target price of HKD 32.40, indicating a potential upside of 43.1% from the current price of HKD 22.64 [10][2][5]. Core Insights - The company is expected to experience high growth driven by BD revenue in 2025, with multiple new products and indications anticipated to be approved, which will help restore product sales to a faster growth trajectory [2]. - The overseas registration of product 707 is progressing rapidly, with milestone revenues expected to continue [2]. - Shareholder returns are projected to strengthen, with cash reserves expected to reach RMB 20.4 billion by year-end, doubling from 2024, and plans for increased dividends in 2026 [5][2]. Financial Forecast Changes - Revenue for 2026 is projected at RMB 10,103 million, a decrease of 21% from previous forecasts, with a net profit forecast of RMB 2,467 million, down 45% [4][11]. - The gross profit margin is expected to be 86.3% for 2026, reflecting a decline of 2.0 percentage points from prior estimates [4]. - The company anticipates a recovery in product sales in 2026, with significant contributions from new products and indications [5][2]. Stock Performance - The stock has shown a 52-week high of HKD 35.90 and a low of HKD 10.12, with a market capitalization of HKD 56,546.80 million [4]. - Year-to-date performance has seen a decline of 6.37% [4]. Revenue and Profitability Projections - The company forecasts a gradual increase in revenue from RMB 10,103 million in 2026 to RMB 22,256 million by 2035 [6]. - The EBIT is expected to rise from RMB 2,879 million in 2026 to RMB 7,812 million by 2035, indicating a positive trend in operational profitability [6]. Cash Flow and Financial Ratios - The free cash flow is projected to be RMB 2,472 million in 2026, with a steady increase expected in subsequent years [6]. - The net profit margin is expected to be 24.4% in 2026, with a gradual improvement to 25.1% by 2028 [12].

Core Viewpoint - The article discusses the development of a novel super-resolution microscopy technique called mirror-enhanced 4Pi single-molecule localization microscopy (me4Pi-SMLM), which simplifies the traditional 4Pi-SMLM system while maintaining high precision in three-dimensional imaging [3][4]. Group 1 - The traditional 4Pi-SMLM technology faces a core limitation of anisotropic resolution, where axial resolution is typically 2-3 times worse than lateral resolution, making it difficult to accurately resolve complex three-dimensional cellular structures [2]. - The new me4Pi-SMLM technique replaces the second objective lens with a mirror, significantly simplifying the system structure and reducing hardware costs and maintenance difficulties while achieving comparable high-precision three-dimensional imaging capabilities [3][4]. - The core innovation of me4Pi-SMLM lies in its design, which uses a single objective lens and a mirror to create controllable interference patterns, enhancing axial localization precision by approximately five times [7]. Group 2 - The research team validated the performance of me4Pi-SMLM by imaging typical subcellular structures such as microtubules and nuclear pore complexes, demonstrating its superior three-dimensional super-resolution imaging capabilities [9]. - The technique allows for dual-color imaging, enabling the observation of spatial relationships between different cellular structures, and has been successfully applied to thicker samples with accurate localization across larger depth ranges [10]. - me4Pi-SMLM is not limited to fixed samples; it can also be applied to live-cell imaging, three-dimensional single-molecule tracking, and thick tissue imaging, achieving resolutions of 40-60 nanometers in live cells and 6 nanometers in single-molecule tracking [12]. Group 3 - The significance of this research lies in its ability to make high-precision three-dimensional super-resolution imaging more accessible, reducing system complexity and maintenance challenges while offering compatibility and upgrade potential for existing 3D-SMLM platforms [12]. - The advancements provided by me4Pi-SMLM are expected to broaden the application of high-precision imaging in various fields of life sciences, including cell biology, neuroscience, and disease mechanism research [12].

Core Insights - The report identifies a bottom reversal in the weight loss drug theme, indicating potential investment opportunities in this sector [1][3]. Group 1: Theme Outputs - New themes identified include lithium mining, which has shown a right-side breakout [3][6]. - Ongoing trends include hydropower, which has been classified under a right-side trend [3][9]. - New themes showing signs of bottom stabilization include new energy vehicles, robotics, national team stocks, and Hang Seng automotive [3][14]. - Newly identified themes indicating bottom reversal include weight loss drugs, cross-strait integration, low-priced small-cap stocks, and car paint [3][16]. Group 2: Right-Side Breakout Opportunities - Lithium mining index has a 5% fund holding ratio, with a 5-day increase of 17% and a year-to-date increase of 3% [7]. - Photovoltaic inverter index has a 10% fund holding ratio, with a 5-day decrease of 5% but a year-to-date increase of 12% [7]. Group 3: Right-Side Trend Opportunities - Hydropower index has a 3% fund holding ratio, with a 5-day increase of 5% and a year-to-date increase of 11% [9]. Group 4: Bottom Stabilization Opportunities - New energy vehicle index has a 2% fund holding ratio, with a 5-day increase of 0% and a year-to-date decrease of 5% [14]. - Robotics index has a 4% fund holding ratio, with a 5-day increase of 1% and a year-to-date decrease of 13% [14]. - National team index has a 4% fund holding ratio, with a 5-day decrease of 2% and a year-to-date decrease of 5% [14]. Group 5: Bottom Reversal Opportunities - Weight loss drug index has a 7% fund holding ratio, with a 5-day increase of 2% and a year-to-date decrease of 5% [16]. - CAR-T therapy index has a 7% fund holding ratio, with a 5-day increase of 1% and a year-to-date decrease of 2% [16]. - Innovative drug index has a 7% fund holding ratio, with a 5-day increase of 3% and a year-to-date decrease of 3% [16].

财联社3月29日电，海南自由贸易港民营企业座谈会在海口召开。 会上，省直有关部门介绍海南自由贸易港建设进展及人工智能发展有关情况，解读海南自由贸易港财税政策；现 场发布海南首批人工智能应用场景；顺丰集团、东超科技、华大基因、商汤科技等15家民营企业代表参会，围绕 强化场景牵引、深化生态协同，加快推动人工智能技术落地应用，赋能产业提质增效等深入交流。 财联社3月29日电，海南自由贸易港民营企业座谈会在海口召开。 会上，省直有关部门介绍海南自由贸易港建设进展及人工智能发展有关情况，解读海南自由贸易港财税政策；现 场发布海南首批人工智能应用场景；顺丰集团、东超科技、华大基因、商汤科技等15家民营企业代表参会，围绕 强化场景牵引、深化生态协同，加快推动人工智能技术落地应用，赋能产业提质增效等深入交流。 ...

Group 1: Robotics and Hard Technology - Faou Robotics successfully completed nearly $100 million in Series C financing, led by the Guoshou Capital under China Life Investment, with continued support from existing shareholders [27] - Ailit Robotics announced the completion of 600 million RMB in D+ round financing, with participation from multiple AIDC industry chain CVC funds and other significant investors [28] - Hangxing Transmission announced over 100 million RMB in Pre-B round financing, with investments from CRRC Guochuang and other entities [12] Group 2: Health and Biotechnology - Shanghai Zhuanma Biotechnology completed several million RMB in Pre-A round financing, with investors including Zeyue Venture Capital and Yifeng Zhuohua Fund [35] - Guangzhou Saiyun Biotechnology announced over 100 million RMB in Pre-C round financing, led by Taiping Medical Health Fund and other investors [37] - Mai Bo Zhi Xing completed nearly 100 million RMB in angel round financing, led by Longpan Investment [33] Group 3: Internet and AI Applications - AI4Materials company Kaiwu Ji announced the completion of several hundred million RMB in angel+ round financing, led by Monolith and supported by several prominent investors [46] - Dingxi Zhichuang completed angel+ round financing, with investments from Jingtai Technology and Shanghai Future Industry Fund [49] - GIM announced the completion of several million RMB in angel round financing, with participation from Wuyuan Capital and Monolith [48]

大成生化科技 分时图 日K线 周K线 月K线 0.06 0.00 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.06 0.06 0.06 0.06 0.06 0.06 0.06 09:30 10:30 12:00/13:00 14:00 16:10 0 65万 130万 195万 公告称，于本年度大部分时间，由于国内市场竞争激烈，集团已将其氨基酸业务的生产设施产能最大 化，故集团的销量增加约36.6%至52.2万公吨(2024年：38.2万公吨)。然而，欧盟及美国自2025年下半年 起对中国的赖氨酸产品征收最终反倾销税，并展开反补贴税调查。因此，本地供应商倾向将氨基酸产品 转售至国内市场，而为应对中国氨基酸产品供应过剩，集团已于2025年第四季度调整氨基酸产量，以达 致最佳生产开工率。 大成生化科技(00809)发布截至2025年12月31日止年度业绩，该集团取得收益22.79亿港元，同比增加 13.86%;本年度溢利1.56亿港元，同比减少79.69%;每股基本盈利1.4港仙。 ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $0.5 million, with $0.4 million from U.S. sales of 25 Symvess units, and total revenue for the year was $2.0 million, with $1.4 million from U.S. sales of 61 Symvess units [17][22] - Net loss for Q4 2025 was $24.8 million, compared to a net loss of $20.9 million for Q4 2024, while the net loss for the year was $40.8 million, significantly reduced from $148.7 million in 2024 [23] - Cash and cash equivalents stood at $50.5 million as of December 31, 2025, with additional funding raised post-quarter [24] Business Line Data and Key Metrics Changes - The commercial launch of Symvess has seen 27 hospitals ordering the product, with a reorder rate from these hospitals [5][8] - Q4 product sales for Symvess were $0.4 million, with a total of $1.4 million for the year, indicating initial traction in the market [5][17] - The company has received a $1.475 million purchase commitment for clinical evaluation in Saudi Arabia, indicating international expansion efforts [7] Market Data and Key Metrics Changes - The success rate for VAC submissions for Symvess is approximately 70%, with 27 VAC approvals in the U.S. and 43 additional reviews ongoing [5][30] - The company is engaging with group purchasing organizations (GPOs) to streamline the contracting process, which could enhance market penetration [31] Company Strategy and Development Direction - The company is focused on expanding the commercialization of Symvess into international markets, including Saudi Arabia and Israel, while also advancing other bioengineered vessel programs [4][7] - Plans to submit a supplemental BLA for dialysis access in the second half of 2026, contingent on positive interim results from ongoing trials [15][35] - The company is also preparing for first-in-human studies for its coronary tissue engineered vessel (CTEV) later in 2026 [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the positive response to the new pricing of Symvess at $17,000, which aligns it competitively with other vascular products [30] - The company anticipates continued growth in adoption rates for Symvess, driven by positive clinical outcomes and surgeon feedback [32][56] - Management acknowledged the challenges in the biotech financing market but emphasized a focus on reducing cash burn and exploring business development opportunities [75][78] Other Important Information - The company has initiated a credit facility providing up to $77.5 million in new financing, which includes an initial tranche of $40 million [24] - The company is actively working on training military surgeons to utilize Symvess, leveraging funding from the U.S. Department of Defense [62] Q&A Session Summary Question: How are sites responding to the new pricing of Symvess? - Management noted a positive response to the $17,000 price point, leading to higher VAC approval rates and increased usage [30] Question: What are the expectations for trauma adoption in the coming year? - Management indicated it is too early to guide but noted that the price change and published long-term data have positively impacted adoption [32] Question: How important is the sales cycle in relation to SG&A? - Management is focusing on expanding the sales team domestically while also partnering for international commercialization efforts [40] Question: What is the expected revenue flow from contracts in Saudi Arabia? - Initial orders are expected to be chunky, with a strategy to distribute products across multiple medical centers [52] Question: What is the status of VAC approvals and their conversion to procurement? - Management indicated that the lower price point has improved the speed of getting products on shelves post-VAC approval [66] Question: Will the pricing in Saudi Arabia differ from the U.S.? - Management anticipates that pricing in Saudi Arabia may be higher than the U.S. due to additional logistics and distribution costs [68]

香港交易及結算所有限公司、香港聯合交易所有限公司（「香港聯交所」）及香港中央結算有限公 司（「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 杭州德適生物科技股份有限公司 除本公告另有界定者外，本公告所用詞彙與杭州德適生物科技股份有限公司（「本公司」）所刊發 日期為2026年3月20日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅供參考，並不構成任何人士收購、購買或認購本公司任何證券的要約或誘使作出要約 的邀請。本公告並非招股章程。有意投資者於決定是否投資於發售股份前，務請細閱招股章 程，以獲得下文所述有關全球發售的詳細資料。任何有關發售股份的投資決定應僅依賴招股章 程所載的資料作出。 本公告概不構成要約出售或招攬要約購買發售股份，而在任何作出有關要約、招攬或出售即屬 違法的司法權區內，概不得出售任何發售股份。本公告不得直接或間接於或向美國或法律禁止 有關派發的任何其他司法權區發佈、刊發或派發，而本公告亦並非在美國或任何其他司法權區 出售或遊說購買或認購證券的要約。發售股份並 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data readouts for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - The company is projected to generate revenue of RMB 1.30 billion in 2025, a 24% year-on-year increase, primarily from overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is forecasted to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is expected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - Revenue projections for 2026E are set at USD 85 million, with gross profit expected to be USD 33 million, maintaining a gross margin of 39.3% [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of registration studies for non-small cell lung cancer (NSCLC). Additionally, the confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are highlighted as key developments [6][12].